Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 13
---
 applicable selling stockholder would pay us the exercise price
of $0.025 per share.

We expect that the selling
shareholders will sell their Ordinary Shares represented by Depositary Shares as described under “Plan of Distribution.”

| 10 |

<div align='center'>DIVIDEND POLICY</div>

Since
inception, we have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends on
our Ordinary Shares or the Depositary Shares in the foreseeable future. We intend to retain all available funds and any future earnings
to fund the development and expansion of our business. As a result, investors in the Ordinary Shares and Depositary Shares will benefit
in the foreseeable future only if the Ordinary Shares and Depositary Shares appreciate in value.

Any
determination to pay dividends in the future would be at the discretion of our Board of Directors and will depend upon our results of
operations, cash requirements, financial condition, contractual restrictions, and any future debt agreements and is subject to compliance
with applicable laws, including the United Kingdom Companies Act of 2006, or the Companies Act, which requires English companies to have
profits available for distribution equal to or greater than the amount of the proposed dividend.

| 11 |

<div align='center'>CAPITALIZATION</div>

The following table sets
forth our capitalization as of June 30, 2025. The information in this table is unaudited and should be read in conjunction with our consolidated unaudited interim financial statements and notes thereto and other financial information incorporated by reference into this prospectus.

| (£ in thousands)          |     | As of June 
 30, 2025   |        |
|:--------------------------|:----|:-----------|-------:|
| Cash and cash equivalents |     |            |  4,036 |
| Long-term debt            |     |            |     -- |
| Total equity              |     |            | 11,436 |
| Total capitalization      |     |            | 11,436 |

The table above does not include, as of June
30, 2025:

| · | 313,070,788                                                                              
 Ordinary Shares issuable upon the exercise of stock options outstanding under our equity 
 incentive plans at a weighted-average exercise price of £0.005                           
 per share;                                                                               |

| · | six                                                                                                
 Ordinary Shares issuable upon exercise of stock options assumed in connection with the acquisition 
 of DARA Biosciences, Inc